Nippon Shinyaku Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The key feature of the quarter was higher revenue and earnings, driven primarily by the Pharmaceuticals Business, while maintaining an operating margin above 25% despite increased R&D investment. Revenue was ¥49.07B (+24.1% YoY), operating income was ¥12.31B (+22.1%), and net income attributable to owners of the parent was ¥10.11B (+22.5%). The increase in revenue was driven by growth in the core Pharmaceuticals segment. Despite a +48.6% increase in R&D expenses, the Company controlled the growth of SG&A expenses, while an increase in other income also contributed to higher earnings.

Factors Affecting Results

【Revenue】Revenue of ¥49.07B (+24.1% YoY) was driven by the Pharmaceuticals Business, which accounts for 88.2% of the revenue mix and recorded revenue growth of +26.6%. The Functional Food Business also contributed on a complementary basis, with revenue growth of +8.0%, and both segments remained on a growth trajectory.

【Profitability】Operating income was ¥12.31B (+22.1%). The gross margin declined to 63.9% from 68.0% in the prior-year period, a decrease of 4.1pt; however, revenue growth (+24.1%) exceeded the increase in SG&A expenses (+10.8%). In addition, other income of ¥1.36B, including gains on sales of non-current assets, supported earnings. R&D expenses increased significantly to ¥9.20B (+48.6%), reaching 18.7% of revenue, likely reflecting a strategic strengthening of pipeline investment. Profit before tax was ¥12.96B (+23.4%), while net income attributable to owners of the parent was ¥10.11B (+22.5%). After deducting income taxes and other taxes of ¥2.85B (effective tax rate: 21.9%), the resulting level was broadly in line with the prior year. This was a higher-revenue, higher-earnings quarter in which the downward pressure from the lower gross margin was absorbed through expense efficiency and other income.

Segment Analysis

The Pharmaceuticals Business generated revenue of ¥43.26B (+26.6% YoY) and operating income of ¥11.28B (+13.5%), with a margin of 26.1%, making it the core earnings pillar and accounting for the vast majority of Company-wide earnings (97.7% of total segment profit). However, profit growth of +13.5% remained below revenue growth of +26.6%, suggesting that the increase in R&D expenses somewhat pressured the segment’s profit margin. The Functional Food Business recorded substantial growth, with revenue of ¥5.81B (+8.0%) and operating income of ¥0.26B (+57.5%), while its margin improved to 4.5%. Although small in scale, the high earnings growth rate indicates a qualitative improvement in the earnings structure.

Key Financial Indicators

【Profitability】The operating margin was 25.1%, maintaining a broadly flat level compared with 25.5% in the same period of the prior year. The gross margin declined to 63.9% from 68.0%, a decrease of 4.1pt, but the impact on the final profit margin was limited due to the recognition of other income. The net profit margin, based on net income attributable to owners of the parent, was 20.6%, a slight decline from 20.9% in the prior year. 【Cash Quality】Operating Cash Flow (OCF) was only 0.18 times net income, indicating that the conversion of earnings into cash is lagging. 【Investment Efficiency】ROE was 3.4% (quarterly actual), while the high equity ratio of 85.6% was one factor relatively constraining capital efficiency. 【Financial Soundness】The equity ratio was 85.6%, up 1.4pt from 84.2% in the prior year. The Company maintained substantial liquidity, with current assets of ¥183.18B against current liabilities of ¥39.34B. Total liabilities were ¥49.42B, or only 14.3% of total assets, indicating an extremely conservative financial structure.

Cash Flow Analysis

Operating CF was ¥1.83B, a significant decrease of -73.0% from ¥6.798B in the same period of the prior year. The primary factors were working capital and tax payment pressures, including an increase in trade receivables (-¥4.34B), a decrease in trade payables (-¥1.96B), and income taxes paid (-¥7.33B). The subtotal after adjustments for non-cash items was ¥8.49B, indicating that the underlying cash-generation capacity itself was maintained. Investing CF was -¥2.32B, with capital expenditures of ¥1.20B and acquisitions of intangible assets of ¥1.60B constituting the main expenditures. Financing CF was -¥4.37B, primarily reflecting dividend payments of ¥3.95B. Free cash flow (operating CF + investing CF) was -¥0.48B, reversing from positive territory in the prior year. The Company was therefore unable to fully fund dividend payments from internally generated funds, and cash and cash equivalents decreased by ¥3.89B from the end of the previous fiscal year to ¥72.70B at period-end.

Quality of Earnings

Current-period earnings benefited from other income of ¥1.36B, including a gain on the sale of non-current assets of ¥0.47B, and finance income of ¥0.69B. Although small relative to revenue, these items have partially non-recurring characteristics. Income taxes and other taxes of ¥2.85B, representing the difference between profit before tax of ¥12.96B and net income of ¥10.11B, resulted in an effective tax rate of 21.9%, with no significant divergence from the prior year and no apparent distortion in the tax burden. Comprehensive income was ¥8.02B, below net income of ¥10.11B, due to other comprehensive income of -¥2.09B. Within this amount, valuation differences on FVTOCI financial assets were significant at -¥2.21B, reflecting the impact of market valuation fluctuations. The fact that operating CF remained at 0.18 times net income was primarily attributable to increased working capital and the concentration of tax payments during the period. From an accrual perspective, progress in reducing working capital going forward will be an important focus in assessing earnings quality.

Earnings Forecasts and Guidance

Progress toward the full-year forecast was 24.5% for revenue (full-year forecast of ¥200.00B), 32.4% for operating income (full-year forecast of ¥38.00B, expected to increase +7.1% YoY), and 33.4% for net income (based on the net income forecast). Revenue was therefore close to the simple benchmark of 25%, while earnings were progressing at a pace above that level. As of the quarter-end, no revisions had been made to the earnings or dividend forecasts. The lead in earnings progress is considered to reflect the high profitability of the Pharmaceuticals Business, together with the boost from other income and finance income.

Shareholder Returns

The full-year dividend forecast is ¥124 per share. Calculated using the number of shares after deducting treasury shares from issued shares (approximately 67.40 million shares), total annual dividends are estimated at approximately ¥8.36B, resulting in a payout ratio of approximately 27.6% against the full-year net income forecast of ¥30.30B. The ¥3.95B dividend payment recorded in the cash flow statement for the quarter represents payment pursuant to the dividend resolution based on the prior fiscal year’s results and does not correspond to current-period earnings. Although free cash flow for the quarter was negative at -¥0.48B, the Company had ample cash and cash equivalents of ¥72.70B. From the perspective of securing funds for dividends, the strong financial foundation reflected in the equity ratio of 85.6% provides support.

Risk Factors

1. Gross Margin Decline Risk: The gross margin was 63.9%, down 4.1pt from 68.0% in the prior year. This suggests changes in the product mix and cost structure. If the downward trend continues, maintaining the operating margin will become increasingly dependent on other income and expense efficiencies.

2. Business Concentration Risk: The Pharmaceuticals Business accounts for 88.2% of revenue and 97.7% of segment profit, indicating a high degree of dependence on a single business. Although the Functional Food Business is trending toward improvement, with earnings growth of +57.5%, its contribution to Company-wide earnings remains limited in terms of scale.

3. Risk of Lower Working Capital Efficiency and Cash Generation: Operating CF decreased by -73.0% YoY to ¥1.83B, representing only 0.18 times net income of ¥10.11B. The key factors were an increase in trade receivables (-¥4.34B) and a decrease in trade payables (-¥1.96B). If this condition persists, it could affect the stability of free cash flow.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Both the operating margin and net profit margin significantly exceeded the industry median, placing profitability among the higher levels within the industry.

Growth and Capital Efficiency

Revenue growth also substantially exceeded the industry median, placing the Company among the industry’s top-tier growth performers.

※Source: Compiled by the Company

Key Points from the Financial Results

1. While profitability and growth are at high levels within the industry, the operating CF/net income ratio is low at 0.18 times, indicating an issue with the speed of earnings conversion into cash. The primary causes were increased trade receivables and concentrated income tax payments, making future working capital trends an important focus in evaluating the quality of the results.

2. R&D expenses expanded to 18.7% of revenue (+48.6%), and the cost structure is changing alongside the decline in the gross margin. How this increased investment is reflected in the future product lineup will be a factor affecting the medium-term earnings structure.

3. Progress toward the full-year earnings forecast was 32.4% for operating income and 33.4% for net income, exceeding the simple benchmark of 25%. Against the strong financial foundation represented by an equity ratio of 85.6%, the key focus will be whether working capital normalizes during the second half of the fiscal year.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥4,490–¥4,757 at ±1% for the cost of equity, and ¥4,615–¥4,629 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual income model / Interest rate reference month: 2026-07 / This value does not predict or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.

---End of Report---